Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

Inclusion Criteria

• •Histologically confirmed non-Hodgkin Lymphoma including small lymphocytic lymphoma, lymphoplasmacytic lymphoma, follicular center cell lymphoma, mantle cell lymphoma, marginal zone lymphoma, diffuse large B cell lymphoma, Burkitt's lymphoma, lymphoblastic lymphoma, anaplastic large cell lymphoma, nasal NK/T cell lymphoma, mycosis fungoides/Sezary syndrome, angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphomas not otherwise specified
• •Received 2 or \> prior therapies, which may include hematopoietic cell transplant (HCT)
• •Received treatment with a nucleoside analog, or an alkylating agent, an anthracycline and/or in the case of B cell lymphomas, rituximab
• •Resistant disease to 2 regimens or resistant disease to at least 1 regimen after first relapse
• •Bi-dimensionally measurable disease documented within 30 days prior to enrollment. Bidimensionally measurable disease is defined as:
• •* A lymph node or tumor mass that can be accurately measured in two dimensions by CT,MRI, medical photograph (skin or oral lesion), plain X-ray, PET scan or other conventional technique and a greatest diameter of 1 cm or \>; or palpable lesions with both diameters \> 2 cm (lesion measured in 2 largest perpendicular dimensions in millimeters)
• •* For the purposes of this protocol, disease should be located in an area of no prior radiation therapy or a clear progression in an area that was previously irradiated
• •Adequate organ and marrow function obtained \< or = to 14 days prior to enrollment as defined by a(n):
• •* ANC \> or = to 1,000/microliter
• •* Platelet count \> or = to 100,000/microliter, or \> or = to 75,000/microliter if the bone marrow is involved
• •* Hemoglobin level \> or = to 9 g/dL
• •* Total bilirubin \< or = to 1.5 x institutional upper limit of normality (ULN).(If abnormal, direct bilirubin less than or equal to 1.5 x institutional ULN)
• •* ALT or AST \< or = to 2.5 x institutional ULN (\< or = to 5 x institutional ULN if liver involvement with lymphoma)
• •* Serum creatinine \< or = to 1.5 x institutional ULN
• •Zubrod (ECOG) Performance Status of 0 or 1
• •Age \> than or = to 18 years
• •Life expectancy \> or = to 3 months as clinically determined by referring physician
• •Female patient is either post menopausal, free from menses for \> 2 years, surgically sterilized or willing to use highly effective methods of contraception (i.e., a condom in conjunction with a diaphragm, or spermicidal jelly; or oral, injectable, or implanted birth control; or abstinence ) to prevent pregnancy throughout the study, starting with visit 1
• •Female patients of childbearing potential must have a negative serum pregnancy test (beta-HCG) within 72 hours of enrollment and should not be nursing due to the potential for congenital abnormalities and of harm to nursing infants due to this treatment regimen
• •Male patient agrees to use an adequate method of contraception (i.e., a condom if female partner uses a diaphragm, spermicidal jelly; or oral, injectable, or implanted birth control; or abstinence) for the duration of the study and for 12 weeks after the last dose
• •Patient must be able to swallow capsules
• •Signed and dated IRB/ethics committee-approved informed consent before any protocol specific screening procedures are performed
• •Both men and women of all races and ethnic groups are eligible for this trial